16.65  -0.56 (-3.25%)		10-30 16:00
Open: 15.51 High: 17.04 Volume: 960,843		Pre. Close: 17.21 Low: 15.51 Market Cap: 2,215(M)

Short term
Mid term
Targets	6-month :	20.53	1-year :	23.98
Resists	First :	17.57	Second :	20.53
Pivot price	16.83
Supports	First :	16.27	Second :	15.47
MAs	MA(5) :	17.1	MA(20) :	16.64
	MA(100) :	16.2	MA(250) :	15.62
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	75.6	D(3) :	84.4
RSI	RSI(14): 49.4
52-week	High :	19.25	Low :	12.78

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AUPH ] has closed above bottom band by 35.1%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	17.06 - 17.15	17.15 - 17.23
Low:	15.3 - 15.41	15.41 - 15.5
Close:	16.48 - 16.65	16.65 - 16.8

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Sat, 31 Oct 2026
AUPH SWOT Analysis: Strong Revenue Growth and Market Position Highlighted in 10-Q Filing - GuruFocus

Fri, 30 Oct 2026
Aurinia Pharmaceuticals Stock Price Forecast. Should You Buy AUPH? - StockInvest.us

Fri, 30 Oct 2026
Aurinia Pharmaceuticals Reports Q3 2026: EPS of $0.23 Exceeds Es - GuruFocus

Fri, 30 Oct 2026
AUPH: Higher 2026 revenue guidance accompanies rising sales and earnings - TradingView

Fri, 30 Oct 2026
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates - Yahoo Finance

Fri, 30 Oct 2026
Aurinia: Q3 Earnings Snapshot - 10tv.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	133 (M)
Shares Float	129 (M)
Held by Insiders	6.7 (%)
Held by Institutions	60.6 (%)
Shares Short	7,920 (K)
Shares Short P.Month	8,980 (K)

EPS	2.27
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.63
Profit Margin	100.8 %
Operating Margin	55.6 %
Return on Assets (ttm)	15.4 %
Return on Equity (ttm)	66.1 %
Qtrly Rev. Growth	18.8 %
Gross Profit (p.s.)	1.82
Sales Per Share	2.34
EBITDA (p.s.)	1.35
Qtrly Earnings Growth	75.5 %
Operating Cash Flow	175 (M)
Levered Free Cash Flow	148 (M)

PE Ratio	7.3
PEG Ratio	0
Price to Book value	3.59
Price to Sales	7.11
Price to Cash Flow	12.64

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.